Daiichi Sankyo Expands Business In Turkey, India
This article was originally published in PharmAsia News
Daiichi Sankyo is expanding operations in India and Turkey as it builds its sales networks. The Japanese drug maker said the first expansion is in Turkey with its Daiichi Sankyo Ilac Ticaret wholly owned subsidiary. The Turkey unit already is operating, with 20 medical representatives to market Daiichi's Evista (raloxifene hydrochloride) osteoporosis treatment. The India entry is expected to begin in June with Daiichi's promotion agreement with GlaxoSmithKline of the U.K. (Click here for more - may require a subscription
You may also be interested in...
Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.
Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue
Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.